Piper Sandler Affirms Overweight Rating for Edwards Lifesciences Ahead of Key Study Results

Piper Sandler has reaffirmed its Overweight rating for **Edwards Lifesciences Corporation** (NYSE:EW) and set a price target of **$90** ahead of the anticipated results from the **PARTNER 3 study**. The findings from this significant study are scheduled to be presented on **October 27, 2023**, during the **Transcatheter Cardiovascular Therapeutics (TCT) conference**.

The PARTNER 3 trial is notable for its extended follow-up period of ten years. It evaluates the effectiveness of **surgical aortic valve replacement (SAVR)** compared to the **Sapien 3 transcatheter aortic valve replacement (TAVR)** in low-risk patients. Analysts from Piper Sandler expect the forthcoming data to indicate that TAVR is not inferior to SAVR concerning key endpoints. They suggest that the results may be regarded as a “non-event with minimal commercial implications,” reflecting a stable outlook for the company.

Edwards Lifesciences specializes in developing and selling patient-focused medical innovations. These include transcatheter heart valves and hemodynamic monitoring systems specifically designed for the treatment of structural heart disease and critical care needs. The company’s focus on innovative solutions has positioned it as a leading player in the medical device sector.

While Piper Sandler acknowledges the growth potential of Edwards Lifesciences, it also highlights a competitive landscape. Some analysts believe that certain artificial intelligence (AI) stocks may offer greater potential for higher returns with limited downside risk compared to Edwards. This perspective invites investors to consider a broader range of options within the market.

In summary, the reaffirmation of the Overweight rating and the upcoming presentation of the PARTNER 3 study results underscore the ongoing significance of Edwards Lifesciences in the medical device industry. As the company continues to evolve, its performance will be closely monitored by investors and analysts alike.